GB1211
oral galectin-3 inhibitor Ph. I/II candidate in cancer and liver diseases LLE and PK opt. from a prev. clinical candidate J. Med. Chem., Sep 26, 2022 Galecto Biotech, Gothenburg, SE
Molecules of the Month - September 2022
4 minute read
Oct. 29, 2022
GB1211: an Oral Galectin-3 Inhibitor for Fibrotic Disease